Analysts' Actions: BRCD COG MCK WAG

NEW YORK ( TheStreet) -- CHANGE IN RATINGS

Brocade ( BRCD) was upgraded at Pacific Crest to Sector Perform. CEO resignation increases the chances of a takeover or company breakup, Pacific Crest said.

Cerner ( CERN) was downgraded at Morgan Stanley from Overweight to Equal-Weight. Bookings growth could slow down in the coming quarters, Morgan Stanley said.

Cabot Oil & Gas ( COG) was upgraded at JP Morgan from Neutral to Overweight. $54.50 price target. Company can grow faster than its peers over the coming quarters, JP Morgan said.

Cymer ( CYMI) was initiated with a Hold rating at Deutsche Bank. Valuation call, based on a $58 price target, Deutsche Bank said.

McKesson ( MCK) was downgraded at Morgan Stanley from Overweight to Equal-Weight. Company is seeing fewer new exclusive generics, Morgan Stanley said.

Molycorp ( MCP) was downgraded from Buy to Hold at Dahlman Rose. Estimates were also cut, following the recent bond offering, Dahlman Rose said.

Walgreen ( WAG) was upgraded at Morgan Stanley from Underweight to Equal-Weight. ESRX overhang has been removed, but European risks remain. Morgan Stanley said.

Wellpoint ( WLP) was downgraded at Morgan Stanley from Overweight to Equal-Weight. Company continues to disappoint with execution, Morgan Stanley said.

STOCK COMMENTS / EPS CHANGES

Agilent Technologies ( A) numbers were cut at Citigroup. Shares are now seen reaching $47. Estimates were also lowered as macro issues lead weak results, Citi said. Buy rating.

Aeropostale ( ARO) estimates were lowered at UBS through 2014. Expect continued margin pressure and share repos likely minimal NT, UBS said. Neutral rating and $14 price target.

Aeropostale estimates, target reduced at Brean Murray. Estimates were cut through 2014. Company lowered its guidance again, Brean Murray said. Buy rating and nwe $18 price target.

Brocade numbers were raised at BMO Capital Markets. Shares are now senn reaching $7. Estimates were also increased on modest increase in revenues and operating margins, BMO said. Market Perform rating.

FedEx ( FDX) estimates, target cut were at Goldman Sachs. Estimates were reduced through 2015. Company should see slower volume growth, Goldman said. Buy rating and new $101 price target.

Gap ( GPS) numbers were raised at UBS. Shares of GPS are now seen reaching $35. Estimates were also increased on improved execution, UBS said. Neutral rating.

Gap estimates, target upped at Lazard. Estimates were boosted through 2013. Company is carrying a lot of sales momentum into the second half of the year, Lazard said. Buy rating and new $45 price target.

Home Depot ( HD) numbers raised at UBS. Shares are now seen reaching $63. Estimates also increased as second half of 2012 sets up well, UBS said. Buy rating.

Marvell Technology ( MRVL) numbers were reduced at Credit Suisse. Estimates were cut through 2014. Company lowered its guidance, Credit Suisse said. Outperform rating and new $18 price target.

Micron ( MU) estimates, price target were cut at Pacific Crest. Shares are now seen reaching $10. Estimates were also reduced, given a weaker PC outlook.

Constellation Brands ( STZ) numbers were boosted at Bank of America/Merrill Lynch. Estimates were also raised, as a tight wine supply should boost pricing, BofA/Merrill said. Buy rating.

SUPERVALU ( SVU) price target was cut at Citigroup to $3. Reflects deteriorating fundamentals and intesifying competition, Citi said. Neutral rating.

>To submit a news tip, email: tips@thestreet.com.

READERS ALSO LIKE:


Follow TheStreet on Twitter and become a fan on Facebook.

This article was written by a staff member of TheStreet.

More from Stocks

Week Ahead: Trade Fears and Stress Tests Signal More Volatility To Come

Week Ahead: Trade Fears and Stress Tests Signal More Volatility To Come

3 Great Stock Market Sectors Millennials Should Invest In

3 Great Stock Market Sectors Millennials Should Invest In

Why Millennials Are Ditching Stocks for ETFs

Why Millennials Are Ditching Stocks for ETFs

Trump's 'Space Force' Could Launch a $1 Trillion Industry, Morgan Stanley Says

Trump's 'Space Force' Could Launch a $1 Trillion Industry, Morgan Stanley Says

Abiomed Stock Should Rise Some 12% From Here, Piper Jaffray Analyst Says

Abiomed Stock Should Rise Some 12% From Here, Piper Jaffray Analyst Says